DZIUREK / SHUTTERSTOCK.COM
How will the OECD’s Modified Nexus Approach to innovator-friendly tax regimes such as the UK’s patent box affect the life sciences industry? LSIPR investigates.
You could say it worked well.
Soon after the UK government announced that it would introduce the patent box, a tax break for innovative companies, GlaxoSmithKline (GSK) and AstraZeneca, the country’s largest pharmaceutical companies, announced plans to expand their operations at home.
GSK reportedly poured £500 million ($771 million) into a manufacturing facility in the UK, created 1,000 new jobs and constructed a new factory, while AstraZeneca invested £120 million, also in a new factory.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
Register here for free content, or subscribe for access to archive.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
OECD, tax, biotechnology, IP, BEPs,
